A10479 | Pages: NA | Jul 2022 | 293 Views | | |
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Antiplatelet Market
Request Now !An antiplatelet drug (antiaggregant), also known as platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that reduces platelet aggregation and hinder thrombus formation. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation, resulting in decreased tendency of platelets to adhere to one another and to endothelium of damaged blood vessels. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease. Antiplatelet therapy with one or more of these drugs decreases the ability of blood clot formation by interfering with the platelet activation process in primary hemostasis. They are useful in arterial circulation, where anticoagulants have lesser effect.
Market scope and structure analysis:
Report Metric | Details |
Market size available for years | 2020–2027 |
Base year considered | 2020 |
Forecast period | 2021–2027 |
Forecast units | Value (USD) |
Segments covered | Product Type, Mode of Administration, and Region |
Regions covered | North America (U.S. and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia Pacific (China, Japan, India, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of LATAM) and Middle East and Africa |
Companies covered | Major players analyzed include Abbott Laboratories, Armetheon Inc., Astrazeneca, Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly, F.Hoffmann-La Roche AG, Genentech, Glaxosmithkline, Johnson & Johnson, Merck, Novartis, and Pfizer Inc. |
COVID-19 scenario analysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
Surge in ageing population is the major factor that propels the antiplatelet market growth. Furthermore, proliferation of antithrombotic/anticoagulant drugs would also help the industry gain traction during the forecast period. Surge in thrombotic events is also anticipated to fuel growth of the industry. Moreover, advancements in the antiplatelet market are expected to help the industry acquire higher revenue in the coming years.
Growth in number of product launches to boost the market
Growth in number of product launches would help the industry flourish in the forecast period. For instance, in June 2020, Medtronic plc, the global leader in medical technology, announced it had received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx.
The approval is the first of its kind globally. Resolute Onyx DES is available for use in the U.S., as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the U.S. Data have been submitted to the FDA with the intent to obtain a one-month DAPT US Indication for Resolute Onyx DES.
Surge in number of mergers and acquisitions to propel the market
Increase in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in September 2020, Mylan planned a megamerger with Pfizer's Upjohn generics unit has had a rocky road to approval, with the novel coronavirus pandemic snagging regulatory review.. Mylan is expected shell out $756 million for European rights to a suite of Aspen Pharmacare's sterile injectable anticoagulants that raked in nearly a quarter-billion dollars in the year ending June 30, the generics giant said Tuesday.
Mylan is expected pay Aspen $310 million in cash upfront with an additional cash payment of $446 million due by June 25, 2021. The deal is expected to close by December 31, roughly in line with the closing date for Mylan's planned merger with Pfizer's Upjohn generics unit.
Key segments covered:
Segments | Subsegments |
Product Type |
|
Mode of Administration |
|
Key benefits of the report:
Questions answered in the antiplatelet market research report:
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers